Inhibitor Therapeutics, Inc.: basic weighted-average shares
Basic weighted-average shares for Inhibitor Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Inhibitor Therapeutics, Inc. financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Reading these values
This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Context from the filing
Inhibitor Therapeutics reports identical basic and diluted weighted-average shares and USD loss per share for 2024 and 2025. Full share counts and the reported rounded EPS are retained. This review confirms the statement presentation only; it does not establish a specific reason for the equal denominators or assert that no potentially dilutive instruments existed. Read the source filing.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 172,511,901 | shares | 2026-03-26 | 10-K · 0001493152-26-012751 |
| 2024-01-01 | 2024-12-31 | 172,262,889 | shares | 2026-03-26 | 10-K · 0001493152-26-012751 |
| 2023-01-01 | 2023-12-31 | 171,950,108 | shares | 2025-03-28 | 10-K · 0001641172-25-001190 |
| 2022-01-01 | 2022-12-31 | 366,183,697 | shares | 2024-03-29 | 10-K · 0001493152-24-011973 |
| 2021-01-01 | 2021-12-31 | 376,247,777 | shares | 2023-03-31 | 10-K · 0001493152-23-010383 |
| 2013-01-01 | 2013-12-31 | 17,940,586 | shares | 2014-04-15 | 10-K · 0001193125-14-144186 |
| 2012-01-01 | 2012-12-31 | 13,646,638 | shares | 2014-04-15 | 10-K · 0001193125-14-144186 |
Related financial histories
- Inhibitor Therapeutics, Inc.: total assets
- Inhibitor Therapeutics, Inc.: total liabilities
- Inhibitor Therapeutics, Inc.: stockholders equity
- Inhibitor Therapeutics, Inc.: cash and cash equivalents
- Inhibitor Therapeutics, Inc.: net income or loss
- Inhibitor Therapeutics, Inc.: operating cash flow
- Inhibitor Therapeutics, Inc.: revenue
- Inhibitor Therapeutics, Inc.: financing cash flow
- Inhibitor Therapeutics, Inc.: retained earnings or deficit
- Inhibitor Therapeutics, Inc.: diluted weighted-average shares
- Inhibitor Therapeutics, Inc.: basic earnings per share
- Inhibitor Therapeutics, Inc.: diluted earnings per share
- Inhibitor Therapeutics, Inc.: income tax expense or benefit
- Inhibitor Therapeutics, Inc.: share-based compensation expense
- Inhibitor Therapeutics, Inc.: operating income or loss
- Inhibitor Therapeutics, Inc.: current assets
- Inhibitor Therapeutics, Inc.: interest expense
- Inhibitor Therapeutics, Inc.: current liabilities
- Inhibitor Therapeutics, Inc.: current accounts payable
- Inhibitor Therapeutics, Inc.: operating expenses
- Inhibitor Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Inhibitor Therapeutics, Inc. / CIK 0001042418
- Captured
- 2026-09-20T05:16:09.831Z
- SEC response SHA-256
4142a89736990e49cb86be8cc08735b878648c52aa079c470055b2d7cd387cb7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001042418.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))